Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.35 |
| ▸ | MERTK | Q12866 | 5/20 | 0.35 |
| ▸ | AXL | P30530 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710520 | 0.85 | ESR1 (0.41) | ESR1ESR2ALDH1A1TYRO3MERTK | |
| SCHEMBL719748 | 0.82 | ESR1 (0.52) | ESR1ESR2CYP11B2HPGD | |
| SCHEMBL722817 | 0.82 | ESR1 (0.51) | ESR1ESR2CYP11B2SMN1; SMN2HPGD | |
| SCHEMBL3715395 | 0.77 | ESR1 (0.48) | ESR1ESR2CYP11B2HPGD | |
| Trifluoroacetic Acid SCHEMBL722173 | 0.76 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL719961 | 0.75 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL3714342 | 0.75 | ESR1 (0.37) | ESR1ESR2ALDH1A1TYRO3MERTK | |
| SCHEMBL718874 | 0.74 | ESR1 (0.43) | ESR1ESR2ALDH1A1CYP11B2SMN1; SMN2 | |
| SCHEMBL2585109 | 0.72 | ESR1 (0.62) | ESR1ESR2 | |
| SCHEMBL719456 | 0.70 | ESR1 (0.56) | ESR1ESR2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | ESR1 1178/4885ESR2 825/4885ALDH1A1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.